Delcath Systems, Inc. Announces Positive Preliminary Results from Phase 3 FOCUS Trial of HEPZATO in Patients with Metastatic Ocular MelanomaGlobeNewsWire • 03/31/21
Delcath Systems Schedules Conference Call to Report 2020 Fourth Quarter Financial ResultsGlobeNewsWire • 03/24/21
Delcath Systems: Cancer-Treatment Device Company With Upcoming Phase 3 ReadoutSeeking Alpha • 02/09/21
Delcath Systems to Present at the H.C. Wainwright Virtual BioConnect ConferenceGlobeNewsWire • 01/11/21
Delcath Systems, Inc. (DCTH) CEO Gerard Michel on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/11/20
Delcath Systems, Inc. to Participate in Oppenheimer Fall MedTech Summit on Thursday, November 12, 2020GlobeNewsWire • 11/02/20
Delcath Schedules Conference Call to Report 2020 Third Quarter Financial ResultsGlobeNewsWire • 11/02/20
Delcath Systems Announces a KOL Call on November 5, 2020 to discuss the Results of a Prospective Phase II Study in Patients with Metastatic Ocular MelanomaGlobeNewsWire • 10/29/20
Delcath Strengthens Executive Team with Appointment of Gerard Michel as Chief Executive OfficerGlobeNewsWire • 10/01/20
Delcath: Peek Of Early Data Of FOCUS Trial Shows Vastly Improved Safety Profile Of ChemosatSeeking Alpha • 09/25/20
Delcath Systems, Inc. to Participate in Upcoming Virtual Investor ConferencesGlobeNewsWire • 09/10/20
Delcath to Present at the LD Micro 500 Virtual Investor Conference on Tuesday, September 1, 2020 at 3:00pm ETGlobeNewsWire • 08/25/20
Delcath Systems, Inc. (DCTH) CEO John Purpura on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/14/20
Delcath Schedules Conference Call to Report 2020 Second Quarter Financial ResultsGlobeNewsWire • 08/06/20
Delcath Systems Announces Pricing of $22 Million Public Offering and Uplisting to the Nasdaq Capital MarketGlobeNewsWire • 05/01/20